Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Paper Test Offers Early Cancer Diagnosis

By LabMedica International staff writers
Posted on 04 Jun 2025

Diagnosing cancer at an early stage remains a significant clinical challenge, particularly in resource-limited settings where access to advanced testing equipment is scarce. More...

Conventional detection methods often struggle to identify cancer-related biomarkers at low concentrations, especially in the early phases of disease. Now, a team of engineers has developed a novel nanoparticle-based sensor that can detect cancer through a simple urine test, offering a potentially affordable, accessible, and rapid diagnostic solution.

The new diagnostic system developed at Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) relies on nanoparticles engineered to respond to tumor-specific enzymes. When these particles reach a tumor, they release short DNA sequences—known as “barcodes”—into the bloodstream, which are later excreted in urine. These DNA barcodes can then be analyzed using a paper-based test strip, similar to at-home COVID-19 tests, using CRISPR technology. A dark line appears when a specific barcode is detected, signaling the presence of cancer-related enzyme activity. To protect the barcodes from degradation in the blood, the researchers used a phosphorothioate modification—a method already applied in stabilizing modern RNA vaccines. Each DNA barcode is linked to a nanoparticle by a cleavable linker responsive to a specific protease—enzymes involved in tumor progression. Once released, the barcode circulates and is ultimately excreted in urine.

The researchers used two types of nanoparticles: one based on FDA-approved polymers and another built from nanobodies—antibody fragments that home in on tumors. The test was designed for multiplexing, meaning it can detect multiple enzyme activities in a single sample, improving both sensitivity and specificity. In research published in Nature Nanotechnology, the scientists used mouse models to demonstrate that five DNA barcodes could accurately distinguish between tumors originating in the lungs and colorectal cancer that had metastasized to the lungs. Additionally, the team designed a microfluidic chip capable of reading up to 46 different DNA barcodes from one sample. These capabilities suggest the test could eventually classify cancer types, monitor treatment responses, and detect recurrence. The broader goal is to make the test scalable and suitable for use in humans. Phase 1 clinical trials conducted of an earlier version of the urinary diagnostic particles has demonstrated their safety in patients.

“We are trying to innovate in a context of making technology available to low- and middle-resource settings,” said MIT scientist Sangeeta Bhatia. “Putting this diagnostic on paper is part of our goal of democratizing diagnostics and creating inexpensive technologies that can give you a fast answer at the point of care.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.